Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDAL: Tarlatamab in DLL3-Positive Metastatic Prostate Cancer
NCT07111507Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Bispecific Antibodies, T-cell Engagers
- Drugs
- tarlatamab
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Radiographic Progression-Free Survival at 24 weeks. Started Jul 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Tarlatamab
Participants receive tarlatamab.
03
Who it enrols
Adult males with DLL3-positive metastatic prostate cancer who have progressed on at least one prior line of therapy, with adequate organ function and ECOG performance status <= 2.
04
Endpoints
Primary
Radiographic Progression-Free Survival
Secondary
Overall Response Rate
Beyond the preview
Go deeper on NCT07111507.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111507.